Cargando…

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study

Background: The risks of osteoporosis and breast cancer are increasing in elderly women. Bisphosphonates and denosumab are recommended for treatment of osteoporosis. They have different and overlapping pharmacodynamics and previous studies have shown conflicting results regarding their risk associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stanoyevitch, Alexander, Zhang, Lei, Sanz, Javier, Follett, Robert W., Bell, Douglas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409235/ https://www.ncbi.nlm.nih.gov/pubmed/34476414 http://dx.doi.org/10.1089/whr.2020.0120

Ejemplares similares

Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland
por: Walsh, Mary E., et al.
Publicado: (2021)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study
por: Marocco, Chiara, et al.
Publicado: (2021)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
por: Benjamin, Biju, et al.
Publicado: (2016)

Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
por: Sydlik, Carmen, et al.
Publicado: (2020)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Nigella sativa: A Potential Antiosteoporotic Agent
por: Shuid, Ahmad Nazrun, et al.
Publicado: (2012)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Antiosteoporotic Activity of Anthraquinones from Morinda officinalis on Osteoblasts and Osteoclasts
por: Wu, Yan-Bin, et al.
Publicado: (2009)

Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment
por: Hu, Mimi I., et al.
Publicado: (2013)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Isolation of Antiosteoporotic Compounds from Seeds of Sophora japonica
por: Abdallah, Hossam M., et al.
Publicado: (2014)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Potential Antiosteoporotic Agents from Plants: A Comprehensive Review
por: Jia, Min, et al.
Publicado: (2012)

Antiosteoporotic Effect of Combined Extract of Morus alba and Polygonum odoratum
por: Sungkamanee, Sudarat, et al.
Publicado: (2014)

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
por: Rajput, Swati, et al.
Publicado: (2023)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
por: Body, Jean-Jacques, et al.
Publicado: (2018)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case Report
por: Georgiadis, George F., et al.
Publicado: (2021)

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study
por: Tsuchiya, Koki, et al.
Publicado: (2021)

Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment
por: Razaq, Abdul, et al.
Publicado: (2019)

Antiosteoporotic effects of Polycan in combination with calcium lactate-gluconate in ovariectomized rats
por: CHOI, JAE-SUK, et al.
Publicado: (2014)

The Antiosteoporotic Activity of Central-Icaritin (CIT) on Bone Metabolism of Ovariectomized Rats
por: Jiang, Jun, et al.
Publicado: (2014)

Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece
por: Rizou, Stavroula, et al.
Publicado: (2017)

PB2142: SERUM OSTEOCALCIN AS A PREDICTOR FOR THE RISK OF DENOSUMAB AND BISPHOSPHONATE INDUCED HYPOCALCEMIA IN MYELOMA PATIENTS WITH HYPERCALCEMIA
por: Ding, Yuehua, et al.
Publicado: (2023)

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
por: Liu, Fang-Chun, et al.
Publicado: (2023)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
por: Hadji, P., et al.
Publicado: (2016)

The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a ‘real-life’ study
por: Fraser, T. R., et al.
Publicado: (2019)

A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives
por: Chatziravdeli, Vasiliki, et al.
Publicado: (2022)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Jiang, Lianghai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rpjoi8v0hlfihe4tbrvhk0bjke